XR Securities’s Akebia Therapeutics AKBA Stock Holding History

XR Securities’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37,000	Closed	-$45K	–	371
2022 Q1	$45K	Buy	+37,000	New	+$79.2K	0.01%	264

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

XR Securities's AKBA Position: Q2 2022 in Review

XR Securities sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 34,306 shares — an estimated $25K sold.

XR Securities first reported a position in AKBA in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

XR Securities reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
XR Securities sold 34,306 Akebia Therapeutics shares in Q2 2022, an estimated $25K.
XR Securities first reported a position in Akebia Therapeutics in Q1 2022 and held it in 1 quarter.
XR Securities's Akebia Therapeutics position peaked at $25K in Q1 2022.
96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on XR Securities's 13F filing for Q2 2022, filed 14 Jul 2022.